12398786.txt 0 antithrombin iii   patients admitted   intensive care units   multicenter observational study
12398786.txt 1 abstract  introduction    administration   antithrombin iii atiii   useful   patients   congenital deficiency   evidence     other therapeutic indications     drug   still uncertain   italy   use   atiii   very common   intensive care units icus     reason   undertook an observational study   determine   pattern   use   atiii   icus     assess   outcome   patients given   treatment  methods    20 may   20 july 2001   consecutive patients admitted   icus   20 italian hospitals   treated   atiii were enrolled   following information was recorded   each patient congenital deficiency indication   use   atiii daily dose   duration   atiii treatment outcome   hospitalization alive   dead   outcome data     observational study were compared   those reported   previously published randomized controlled trials rcts  results  two hundred   sixteen patients were enrolled     study   clinical indications   using atiii were sepsis 259 disseminated intravascular coagulation 231   other clinical conditions 468     end     study 653     patients were alive 245 died   102 were still     hospital among   patients   sepsis n  56 19 died during   observation period 339 95 confidence interval 221 475  discussion    study described   pattern   use   atiii   italian hospitals   provided information     outcome     subgroup treated   sepsis   metaanalysis   current data   rcts together     findings indicates         sound basis   using   drug   icu patients   sepsis
12398786.txt 2 antithrombin iii disseminated intravascular coagulation sepsis septic shock
12398786.txt 3 antithrombin iii atiii     recognized treatment   patients   congenital atiii deficiency  see also   approval     indication     food   drug administration   contrast   evidence supporting its use   other clinical indications   uncertain    italian hospitals   drug   widely used   patients admitted   intensive care units icus who   generally given atiii     treatment   sepsis   disseminated intravascular coagulation dic   approval   atiii     italian ministry   health was granted nearly 10 years ago before   profound reform     drug regulatory agency made     italian ministry   health   1993   has remained unchanged since     approval   atiii was rather generic   included congenital deficiency   atiii     clinical conditions   can cause an acquired deficiency   atiii three small randomized studies    one large international trial  assessed   effectiveness   atiii   sepsis   none   these trials found   significant benefit   terms   reduced morbidity   mortality   regards congenital deficiency   effectiveness   atiii   fairly well documented    these patients   rare   other clinical indications such   acute thrombosis   thromboembolism prevention   dic   hepatic coma   treatment   bleeding episodes   cirrhosis   supported     small series   very preliminary studies see   example   drugdex databank cdrom drugdex volume 110 micromedex englewood colorado usa   achieve   better definition     current use   atiii   italian hospitals     generate naturalistic data based   routine practice about   outcome     treatment   undertook   multicenter observational study
12398786.txt 4 design     study   aims    study was based     multicenter observational design   20 may   20 july 2001   consecutive patients admitted   icus   20 italian hospitals   treated   atiii were enrolled     study   study had   following aims 1 surveying   use   atiii   patients admitted   icus 2 determining   outcome   patients treated   atiii   3 comparing   results obtained     observational study   those previously found     randomized controlled trials rcts   metaanalysis was also conducted   summarize   information deriving   four rcts    studied   effectiveness   atiii   sepsis  data collection    following information was recorded   each patient enrolled     study 1 demographic characteristics age sex weight 2 congenital deficiency yn 3 baseline atiii level 4 ward   first admission     hospital 5 clinical indication   using atiii sepsis   dic   any other clinical condition 6 daily dose   duration   treatment   atiii 7 outcome   hospitalization alive   dead   8 concurrent administration   antibiotics    heparin  analysis    information collected   each patient was analyzed   standard descriptive statistics     subgroup   patients   sepsis    hospital mortality rate observed     study was compared     previously reported     four rcts   rates were presented together   their 95 confidence interval ci   was calculated   using equations 126   127   fleiss 
12398786.txt 5   overall number   patients who were admitted   icus during   study period was 1648   these patients 216 13 were enrolled     study   characteristics   these 216 patients   presented   table  table 1  characteristics     216 patients enrolled     observational study       subgroup   56 patients treated   sepsis   clinical indication   using atiii was sepsis n  56 dic n  50   other n  101 table  also reports separate information     subgroup   56 patients treated   sepsis   duration   atiii therapy did   differ   levels   statistical significance between patients treated   different clinical indications p  057 according   an analysis   variance   daily dose   atiii showed   difference between sepsis   other indications  table  reports   outcome   hospitalization according   clinical indication   regard     use   atiii   patients   sepsis figure  shows   percentage mortality rate   95 ci observed     study together     rates found   four previous studies  figure 1  percentage mortality rate   95 ci   patients   sepsis comparison between   results     observational study   those reported     four rcts previously published percentage mortality rate   95 ci   patients   sepsis comparison between   results     observational study   those reported     four rcts previously published solid lines treatment groups broken lines control groups dates   publication 1993 fourrier et al  early 1998 eisele et al  late 1998 baudo et al  2001 warren et al      study table 2  relationship between clinical indication     use   atiii   outcome   hospitalization subgroup analyses within   patient cohort     study did   identify any relationship between mortality   patient characteristics   administration   heparin   warren et al  found   have some implications   outcome did   influence mortality     patient series mortality was 196     107 patients who received heparin compared   305     95 patients who did   receive   drug p  010   fishers exact test mortality was 286     28 patients   sepsis who received heparin compared   423     26 patients   sepsis who did   receive   drug p  039
12398786.txt 6   main scientific value     observational   prospective study lies   its naturalistic design   population   patients     studied was   fact drawn     everyday practice     than 20 hospitals   was intentionally free   specific exclusion criteria   interpreting   outcome data one disadvantage       group treated   atiii was   compared   any reference group observed prospectively within   research neither did   include any retrospective control group   treated     drug however historical retrospective controls would have raised profound problems   matching   retrospective data     prospective ones   prospective enrollment   controls   treated   atiii was   feasible because   therapeutic policy     icus involved     study was   administer atiii   virtually   patients     diagnosis   sepsis   dic regardless     statistical indexes   firstlook comparison between   data   sepsis produced     previous rcts including four treatment groups   four control groups   those observed     naturalistic study indicates   complete overlap     various survival rates     their respective 95 cis   qualitative impression      agreement     metaanalysis shown   figure  see appendix2   details   its methodology figure 2  comparison   death rates between patients given atiii   patients given placebo     four rcts   met   inclusion criteria   out metaanalysis comparison   death rates between patients given atiii   patients given placebo     four rcts   met   inclusion criteria   out metaanalysis   odds ratios     individual studies       metaanalysis   denoted   dots       diamond respectively each horizontal bar indicates   95 ci     odds ratio     vertical dotted line represents   identity line   top   bottom datasets     trials   warren et al  baudo et al  eisele et al    fourrier et al    bottom dataset     metaanalysis     four rcts   crude death rates     treatment group       control group respectively were   follows fourrier et al  7   17 versus 9   18 eisele et al  5   20 versus 9   22 baudo et al  31   50 versus 33   48 warren et al  450   1157 versus 448   1157   metaanalysis gave   following results summary odds ratio 098 95 ci 083 115 p  080 chi2   heterogeneity 186 3 degrees   freedom p  060     metaanalysis   largescale trial   warren et al  outweighed   other three small rcts     warrens trial included 93     overall cohort     four rcts     light     above data   seems       clinical benefit   administering atiii   critical patients   sepsis     context one crucial point       most recent largescale trial gave very clear results   was negative   other clinical indications reported     patients series were   difficult   interpret because     nearly complete lack   previous controlled studies exploring these therapeutic issues   has been   lively debate     literature     relative merits   observational studies   rcts   providing useful evidence   clinical effectiveness  although   great majority   researchers stick     concept   rcts     gold standard common sense suggests   having information both   rcts     observational studies   better than having information   rcts only     framework   study advances knowledge about   use   atiii   critical patients   conclusion   findings based   an observational prospective study     an updated metaanalysis     previous rcts     support   use     drug   icu patients   sepsis
12398786.txt 7 antithrombin iii atiii     recognized treatment   patients   congenital atiii deficiency   contrast   evidence supporting its use   other clinical indications   uncertain   italian hospitals   drug   widely used   patients admitted   intensive care units icus who   generally given atiii     treatment   sepsis   disseminated intravascular coagulation three small randomized studies   one large international trial have assessed   effectiveness   atiii   sepsis   none   these trials has found   significant benefit   terms   reduced morbidity   mortality   findings based   an observational prospective study     an updated metaanalysis     previous randomized controlled trials     support   use     drug   icu patients without congenital deficiency
12398786.txt 8   2001   research group received   grant   elililly italy   conduct an original study   factors influencing length   stay   critical patients   sepsis   italy antithrombin iii   marketed   aventisbehring     baxter
12398786.txt 9 gruppo di studio sullantitrombina iii   antithrombin study group    antithrombin study group includes   study coordinators   messori f vacca m vaiani s trippoli laboratorio di farmacoeconomia c  azienda ospedaliera careggi firenze     total   51 participants   names   addresses     participants involved     project were   following   located   italy r banfi m cecchi e cini   dupuis   falai r fornaini   ipponi ml migliaccio f pelagotti l rabatti   ruffino r silvano e tendi firenze four hospitals p becagli m monciatti empoli b bozzone r casullo f cattel s pardossi r passera s stecca u tagliaferro torino two hospitals p di bartolomeo   faggiano m lattarulo bari n caboni   cannas cagliari   plescia m sorci rimini l bonistalli m puliti prato b ciammitti m costantini f mammini terni l de cicco g mazzaferro napoli p marrone r tetamo palermo p beneduce mg celeste p fiorani s galeassi g guaglianone   pecere l ragni roma two hospitals sm germinario andria   basadonna l todesco camposampiero padova r callegari m pegoraro asolo e lamura ancona
12398786.txt 10 methodology     metaanalysis    medline search pubmed  was performed   cover   period   january 1980   november 2001   search was limited     studies published   english   was based   four index terms combined     following boolean syntax antithrombin iii   sepsis   septic shock   disseminated intravascular coagulation   search was supplemented   examining   drugdex databank cdrom drugdex volume 110 micromedex englewood colorado usa eligible studies were included     met   following criteria patients were admitted   an icu randomized design diagnosis   sepsis septic shock   dic assessment   survival   odds ratio was used     main index   assess   treatment effect within each trial     generate   overall results     metaanalysis   calculation     summary odds ratios was based     randomeffect model  heterogeneity was assessed   described previously 
12398786.txt 11 atiii  antithrombin iii ci  confidence interval dic  disseminated intravascular coagulation icu intensive care unit rct  randomized controlled trial
12398786.txt 12 
